Home Control International Announces Strategic Move Into Indonesian Healthcare AI Market
Home Control International Limited (Stock Code: 1747), a company incorporated in the Cayman Islands and listed in Hong Kong, has made a significant voluntary announcement regarding its latest business development. The company, through its wholly-owned subsidiary Orbiva Limited, has entered into a Strategic Cooperation Memorandum with PT Articura Tech Indonesia (“Articura”) to explore business opportunities related to localized healthcare AI and digital health solutions in Indonesia.
Key Highlights of the Announcement
- Strategic Cooperation Memorandum Signed: On 23 July 2026, Orbiva Limited signed a memorandum with Articura to establish a framework for exploring the Indonesian healthcare AI market.
- Focus on Localisation: The cooperation centers on developing healthcare AI infrastructure and digital health solutions that comply with Indonesian requirements on data storage, data sovereignty, and regulatory compliance.
-
Exploratory Scope: The memorandum sets out a non-binding intention to collaborate in several critical areas of digital health and AI, including:
- Development and optimization of AI reasoning-rule systems tailored for Indonesia’s healthcare environment.
- Assessment of foundation models, language intelligence, and localized large language model capabilities for healthcare applications.
- Data cleansing, integration, and governance for clinical data from hospitals and clinics, aligned with local disease profiles and healthcare needs.
- Integration of home healthcare devices, digital health records, and AI-driven health management, supporting remote monitoring and personalized healthcare.
- Deployment of AI applications in hospitals, including pre-consultation, patient triage, clinical decision support, and patient follow-up.
- Market Expansion Potential: Subject to successful implementation, Indonesia could become a launchpad for expanding these healthcare AI solutions across other ASEAN markets.
- Potential Investment Cooperation: The memorandum includes provisions for potential investment, but no terms (amount, valuation, etc.) have been agreed. All investments are subject to further negotiation and regulatory approval.
- Legally Binding Aspects: Only clauses relating to confidentiality, data protection, exclusivity (limited to this project), disclosure, dispute resolution, and general provisions are binding. All other terms are non-binding and subject to further agreement.
Details About the Parties
- Orbiva Limited: A wholly-owned subsidiary of Home Control International Limited, headquartered in Singapore, with heritage from Koninklijke Philips N.V.’s home-control division. The group has an established track record in smart devices, global supply chains, and AI-related technology commercialization.
- PT Articura Tech Indonesia: An independent Indonesian company specializing in healthcare AI and digitalization, with experience in deploying AI in healthcare settings.
Investor Considerations and Price-Sensitive Information
- Early Stage and No Government Endorsement Yet: The cooperation is still at the exploratory and assessment phase. No definitive agreements have been signed, nor has any Indonesian government support, approval, or endorsement been obtained at this stage. No projects have been awarded.
- Uncertainty and Caution Advised: There is no certainty that any of the contemplated projects, transactions, or commercial arrangements will materialize. Further announcements will be made if any deal or project arises that requires disclosure.
- Potential Price Sensitivity: The entry into this strategic market and partnership, if successful, could represent a significant expansion into the high-growth healthcare AI sector in Southeast Asia. However, shareholders should note the high degree of uncertainty and exercise caution when dealing in the company’s securities.
Board Composition
- Executive Directors: Mr. Kwok Hoong SIU (CEO), Mr. Haofang YANG
- Non-executive Director: Ms. Ying MA
- Independent Non-executive Directors: Mr. Min YE, Mr. Yi Chung CHEN, Mr. Bernard Eng Chuan LIM
Disclaimer
This article is for informational purposes only and does not constitute investment advice. The information is based on the latest voluntary announcement by Home Control International Limited as of 27 July 2026. Investors should perform their own due diligence and consult professional advisors before making any investment decisions. The cooperation described is at a preliminary stage and may not result in any binding agreement or commercial outcome.
香港家控國際有限公司公佈：進軍印尼本地化醫療AI市場，簽訂策略合作備忘錄
香港家控國際有限公司（股份代號：1747）於2026年7月27日自願公佈，通過全資子公司 Orbiva Limited，與印尼 PT Articura Tech Indonesia（“Articura”）簽訂策略合作備忘錄，探索印尼本地化醫療AI及數字健康市場機遇。
公告重點
- 簽訂策略合作備忘錄： 2026年7月23日，Orbiva與Articura簽訂合作備忘錄，建立探索印尼醫療AI市場的合作框架。
- 聚焦本地化： 雙方合作重點是開發符合印尼數據儲存、主權及監管要求的醫療AI基礎設施及數字健康解決方案。
-
探索範圍： 備忘錄涵蓋多個核心醫療AI與數字健康合作領域，包括：
- 為印尼醫療環境量身打造AI推理規則系統。
- 評估基礎語言模型及醫療AI大語言模型能力。
- 整合與治理醫院、診所臨床數據，對應當地疾病特徵與需求。
- 結合家用健康監測設備、電子健康檔案與AI健康管理，推動遠程監控與個人化醫療。
- 醫院AI應用，包括預診、分流、臨床決策、病人跟進等。
- 區域擴展潛力： 若合作成功，印尼有望成為東盟其他市場醫療AI解決方案擴展的基地。
- 潛在投資合作： 備忘錄亦包括投資合作安排，但尚未有具體金額、估值等協議，一切需經進一步協商及監管審批。
- 法律約束條款： 只有保密、數據保護、專屬性（僅限此計劃）、披露、爭議解決等條款具法律約束力，其餘則屬意向性，需另行協議。
合作方資料
- Orbiva Limited： 家控國際全資子公司，總部位於新加坡，前身為飛利浦家控部門，專長智能設備、供應鏈及AI技術商業化。
- PT Articura Tech Indonesia： 印尼本地醫療AI公司，具醫療數字化及AI落地經驗，與家控國際無關聯。
投資者需關注及可能影響股價事項
- 合作仍屬初步探索，未獲政府支持： 雙方尚未簽署具約束力協議，亦未獲印尼政府任何認可、批準或授權，暫未獲任何項目授出。
- 高度不確定，敬請審慎： 有關合作及項目能否落實具高度不確定性，公司如有重大進展將再行公告，股東應審慎處理股份。
- 潛在價格敏感： 若合作落實，將標誌公司進軍東南亞高增長醫療AI市場具里程碑意義，但目前風險及不確定性高。
董事會組成
- 執行董事：蕭國雄先生（行政總裁）、楊浩芳先生
- 非執行董事：馬瑛女士
- 獨立非執行董事：葉敏先生、陳義忠先生、林映泉先生
免責聲明
本文僅供資訊參考，並不構成投資建議。資料來自家控國際截至2026年7月27日之自願公告。投資者應自行進行盡職調查及諮詢專業顧問。所述合作仍屬初步階段，未必有具體成果或協議。
